These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 15886157)
21. Global vaccine supply. The increasing role of manufacturers from middle income countries. Francis DP; Du YP; Precioso AR Vaccine; 2014 Sep; 32(41):5259-65. PubMed ID: 25110294 [TBL] [Abstract][Full Text] [Related]
22. Strengthening the supply of routinely recommended vaccines in the United States: a perspective from the American Medical Association. Tan L; Clin Infect Dis; 2006 Mar; 42 Suppl 3():S121-4. PubMed ID: 16447133 [TBL] [Abstract][Full Text] [Related]
23. Market incentives, human lives, and AIDS vaccines. Craddock S Soc Sci Med; 2007 Mar; 64(5):1042-56. PubMed ID: 17113203 [TBL] [Abstract][Full Text] [Related]
24. They do things a little differently. Providers branching out internationally face a host of legal, regulatory issues. Blesch G Mod Healthc; 2008 Dec 22-29; 38(51):32-3. PubMed ID: 19175214 [No Abstract] [Full Text] [Related]
25. [Vaccines: producers in countries of the Southern hemisphere]. Bertrand JJ Med Trop (Mars); 2007 Aug; 67(4):347-50. PubMed ID: 17926792 [TBL] [Abstract][Full Text] [Related]
27. The emergence of global health partnerships as facilitators of access to medication in Africa: a narrative policy analysis. Ngoasong MZ Soc Sci Med; 2009 Mar; 68(5):949-56. PubMed ID: 19152991 [TBL] [Abstract][Full Text] [Related]
28. Issues in the design and implementation of vaccine trials in less developed countries. Deen JL; Clemens JD Nat Rev Drug Discov; 2006 Nov; 5(11):932-40. PubMed ID: 17080029 [TBL] [Abstract][Full Text] [Related]
29. Keys to strengthening the supply of routinely recommended vaccines: view from industry. Pisano W Clin Infect Dis; 2006 Mar; 42 Suppl 3():S111-7. PubMed ID: 16447131 [TBL] [Abstract][Full Text] [Related]
30. Improving vaccine supply and development: who needs what? Pauly MV Health Aff (Millwood); 2005; 24(3):680-9. PubMed ID: 15886159 [TBL] [Abstract][Full Text] [Related]
31. Encouraging the development of new vaccines. Grabowski H Health Aff (Millwood); 2005; 24(3):697-700. PubMed ID: 15886162 [TBL] [Abstract][Full Text] [Related]
32. Advance price or purchase commitments to create markets for treatments for diseases of poverty: lessons from three policies. Towse A; Kettler H Bull World Health Organ; 2005 Apr; 83(4):301-7. PubMed ID: 15868022 [TBL] [Abstract][Full Text] [Related]
34. Emerging markets & emerging needs: developing countries vaccine manufacturers' perspective & its current status. Jadhav SS; Gautam M; Gairola S Biologicals; 2009 Jun; 37(3):165-8. PubMed ID: 19328010 [TBL] [Abstract][Full Text] [Related]
35. Development of priority vaccines for disease-endemic countries: risk and benefit. Milstien J; Cash RA; Wecker J; Wikler D Health Aff (Millwood); 2005; 24(3):718-28. PubMed ID: 15886166 [TBL] [Abstract][Full Text] [Related]
36. Financing vaccines: in search of solutions that work. Iglehart JK Health Aff (Millwood); 2005; 24(3):594-5. PubMed ID: 15886147 [No Abstract] [Full Text] [Related]
37. Vaccine venture boosts health hopes. Butler D Nature; 2009 Sep; 461(7262):323. PubMed ID: 19759588 [No Abstract] [Full Text] [Related]
38. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
39. Predicaments during a period of health emergency: Waiving patent protections or innovative public procurement? The example of advance purchase agreements (APA) for COVID-19 vaccines. Garrido Cuenca N Int J Risk Saf Med; 2022; 33(2):145-156. PubMed ID: 35213327 [TBL] [Abstract][Full Text] [Related]